期刊
THESCIENTIFICWORLDJOURNAL
卷 10, 期 -, 页码 413-418出版社
HINDAWI LTD
DOI: 10.1100/tsw.2010.44
关键词
cucurbitacin; cancer; STAT3 inhibitor; JAK-STAT pathway; ERK inhibitor; MAPK pathway; synergism; chemotherapy; doxorubicin; gemcitabine
资金
- Deutsche Forschungsgemeinschaft [TH 1438/1-1]
Cucurbitacins and their derivatives are triterpenoids found in medicinal plants known for their diverse pharmacological and biological activities, including anticancer effects, throughout human history. Although initial attention to cucurbitacin as a potential anticancer drug withered for decades, recent discoveries showing that cucurbitacin is a strong STAT3 (Signal Transducers and Activators of Transcription-3) inhibitor have reclaimed the attention of the drug industry one more time. There is increasing evidence showing that some cucurbitacins not only inhibit the JAK-STAT pathway, but also affect other signaling pathways, such as the MAPK pathway, which are also known to be important for cancer cell proliferation and survival. Moreover, some reports have shown the synergistic effect of cucurbitacins with known chemotherapeutic agents, such as doxorubicin and gemcitabine. In this review, we will summarize the recent discoveries regarding molecular mechanisms of action of cucurbitacins in human cancer cells and discuss the possibilities of cucurbitacin as a future anticancer drug in clinical settings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据